Vinorelbine plus cisplatinum for the treatment of Stage IIIB and IV Non Small Cell Lung Carcinoma.

Mario Latteri, Calogero Cipolla, Vittorio Gebbia, Nicola Gebbia, Vittorio Gebbia, Maurizio Chiarenza, Curto, Verderame, Oliveri, Valenza, Cannata, Calogero Cipolla, Di Gesu, Mario A. Latteri, Michele Caruso, Testa

Risultato della ricerca: Articlepeer review

33 Citazioni (Scopus)


Thirty consecutive patients with stage IIIB-IV non small cell lung cancer were treated with a combination of cisplatin 80 mg/m2 on day 1 plus vinorelbine 25-30 mg/m2 on days 1, 8. This cycle was repeated every 3 weeks. The overall response rate was 46%, with 1 patient showing a complete response and 13 patients (43%) a partial response with a mean duration of 8.4+ months. Six patients had a stabilization and 10 progressed. The main toxicities were represented by myelosuppression and nausea/vomiting. Grade 3 leukopenia was seen in 33% of cases, grade 2 thrombocytopenia in 12%, and phlebitis in the injection vein in 16%. Mild constipation was also recorded. The combination of cisplatin plus vinorelbine is quite effective in advanced non small cell carcinoma of the lung, and may be safely given on an outpatient basis
Lingua originaleEnglish
pagine (da-a)1247-1249
Numero di pagine3
RivistaAnticancer Research
Stato di pubblicazionePublished - 1994

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Entra nei temi di ricerca di 'Vinorelbine plus cisplatinum for the treatment of Stage IIIB and IV Non Small Cell Lung Carcinoma.'. Insieme formano una fingerprint unica.

Cita questo